Navigation Links
Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
Date:3/31/2009

TEMPE, Ariz., March 31 /PRNewswire/ -- Intrinsic Bioprobes, Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two-and-a-half-year contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor's share provided by Intrinsic Bioprobes, Inc. This contract is in support of NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).

"The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids," says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. "The application of proteomics tools in the clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single-step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches," adds Nedelkov.

Intrinsic Bioprobes, Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis
'/>"/>

SOURCE Intrinsic Bioprobes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the industry ... and internationally, intends to open a full service medical ... Mexico , bringing advanced scientific tools and methodology ... Steep Hill is currently the only laboratory licensed ... potency and contaminant testing in order to meet the ...
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... ARLINGTON, Va., July 13 The Generic Pharmaceutical Association ... Kathleen Jaeger on the Senate HELP Committee,s vote on biogenerics legislation. ... disappointed that the Committee action could result in patients having little ... in the House to ensure that a true balance is achieved ...
... 13, 2009) Whitehead Institute scientists have developed a ... target diseases that until now have stymied drug developers, ... yeast to synthesize and screen the molecules, cutting target ... weeks. The current drug discovery process ...
... ERT (Nasdaq: ERES ), a leading provider of ... medical device, and related industries, announced today that it will release ... 2009 after the market closes. After the release, the Company will ... , For the conference call, interested ...
Cached Biology Technology:GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4ERT to Announce 2009 Second Quarter Results on July 30, 2009 2
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... AURORA, Colo. (Dec. 9, 2013) A new study shows ... concussions than those closer to sea-level, a phenomenon attributed to ... tightly in the skull. "This is the first time ... Comstock, PhD, associate professor of epidemiology at the Colorado School ...
... Liver (EASL) today publishes their revised Clinical Practice Guidelines ... (HCV) (1). The EASL guidelines, which supersede the ... physicians and other healthcare providers optimise their management of ... estimated that approximately 160 million individuals, i.e. 2.35% of ...
... of tumours in over one per cent of all cancer ... has been broadly linked to cancer development. The team ... activated that increases tumour growth. Drugs that inhibit the biological ... in development thus highlighting a potential new targeted therapy for ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... designed for flexibility and routine operation. With ... lens, true hyperbolic quadrupole and high-speed simultaneous ... range of sample types and applications. New ... standard Agilents unique ShieldTorch System, which enables ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
Biology Products: